Immunic (IMUX) Stock Price, News & Analysis

Company Overview

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $1.05 to $1.13
• 50-Day Range: $1.05 to $1.95
• 52-Week Range: $0.97 to $2.11
• Volume: 428,596 shs
• Average Volume: 619,512 shs
• Market Capitalization: $100.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.25
• Consensus Rating: Buy

Immunic Stock Analysis - MarketRank™

Immunic scored higher than 63% of companies evaluated by MarketBeat, and ranked 420th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Immunic has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immunic has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunic are expected to grow in the coming year, from ($0.93) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunic is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunic is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunic has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.00% of the outstanding shares of Immunic have been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Immunic has recently increased by 29.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunic does not currently pay a dividend.

Dividend Growth

Immunic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.00% of the outstanding shares of Immunic have been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Immunic has recently increased by 29.68%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.19

News Sentiment

Immunic has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Immunic this week, compared to 3 articles on an average week.

Search Interest

23 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 77% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,395.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Immunic is held by insiders.

Percentage Held by Institutions

51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMUX Stock Analysis - Frequently Asked Questions

How have IMUX shares performed this year?

Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX stock has decreased by 25.7% and is now trading at $1.1150.
View the best growth stocks for 2024 here.

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) issued its earnings results on Thursday, August, 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02.

Who are Immunic's major shareholders?

Immunic's top institutional investors include Janus Henderson Group PLC (5.66%), State Street Corp (0.19%), Connor Clark & Lunn Investment Management Ltd. (0.11%) and Jane Street Group LLC (0.08%). Insiders that own company stock include Daniel Vitt, Andreas Muehler, Richard Alan Rudick, Glenn Whaley, Duane Nash and Joerg Neermann.
View institutional ownership trends.

How do I buy shares of Immunic?

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMUX
• CUSIP: N/A
• CIK: 1280776
• Web: www.immunic-therapeutics.com
• Phone: (332) 255-9818
• Fax: 858-673-6843
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.25
• High Stock Price Target: $28.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +1,023.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-93,610,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -169.55%
• Return on Assets: -118.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.71
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 2.37

Miscellaneous

• Outstanding Shares: 90,080,000
• Free Float: 87,377,000
• Market Cap: $98.19 million
• Optionable: Optionable
• Beta: 1.88